Lv6
2210 积分 2020-06-11 加入
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
5小时前
待确认
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone
7天前
已完结
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone
1个月前
已完结
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
1个月前
已完结
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
1个月前
已完结
EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
1个月前
已完结
Prognostic and predictive biomarkers in non-small cell lung carcinoma
1个月前
已完结
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone
1个月前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
2个月前
已完结
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone
2个月前
已完结
皖公网安备34019202002308
